Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10963672 | Vaccine | 2015 | 10 Pages |
Abstract
HGN194 IgG1 and dIgA2 used alone and the combination of the two neutralized the challenge virus equally well in vitro. All RMs given only i.v. HGN194 IgG1 became infected. In contrast, all RMs given HGN194 IgG1Â +Â dIgA2 were completely protected against high-dose i.r. SHIV-1157ipEL-p challenge. These data imply that combining suboptimal defenses at the mucosal and systemic levels can completely prevent virus acquisition. Consequently, active vaccination should focus on defense-in-depth, a strategy that seeks to build up defensive fall-back positions well behind the fortified frontline.
Keywords
ADCCi.r.dimeric IgAIC90Neutralizing monoclonal antibodyTCID50intrarectalFcγRvRNAFcRni.v.ENVPBSmAbIC50IgGCTL50% tissue culture infectious dose50% inhibitory concentrationViral RNAMonoclonal antibodyPassive immunizationimmunoglobulin IgAIntravenousSHIVdIgAPhosphate buffered salinecytotoxic T lymphocyterhesus monkeysimian-human immunodeficiency virusAntibodyEnvelopeFcγ receptor
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Anton M. Sholukh, Jennifer D. Watkins, Hemant K. Vyas, Sandeep Gupta, Samir K. Lakhashe, Swati Thorat, Mingkui Zhou, Girish Hemashettar, Barbara C. Bachler, Donald N. Forthal, Francois Villinger, Quentin J. Sattentau, Robin A. Weiss, Gloria Agatic,